In the assessment of 12-month price targets, analysts unveil insights for Sangamo Therapeutics, presenting an average target ...

U.S. stock futures were flat on Tuesday after a bounce back on Monday. Futures of all four benchmark indices were mixed in premarket trading.

Shares of clinical-stage biotech firm Sangamo Therapeutics Inc. fell nearly 3% in Monday's after-hours trading following ...

Sangamo (SGMO) delivered earnings and revenue surprises of -22.22% and 52.51%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics Inc. SGMO) on Monday reported a loss of $23.4 million in its fourth quarter.

Sangamo posted a Q4 loss of $0.11 per share, $0.01 worse than the $0.10 loss analysts had forecast. Revenue for the quarter came in at $7.55 million, missing the consensus estimate of $10.32 million.

The company said, “2025 operating expenses on a non-GAAP basis are expected to be roughly in line with 2024, reflecting our intention to ...

Today, several major companies are expected to report earnings: CBAK Energy Technology (CBAT), Sangamo Biosciences (SGMO), ...

"We want to see if we can bring that war to an end," Trump told reporters on Air Force One late Sunday, according to a video published by the Associated Press. "Maybe we can, maybe we can't, but I ...

In a volatile fourth quarter, the Wasatch Ultra Growth Fund—Investor Class returned 0.94% and slightly underperformed the benchmark Russell 2000® Growth Index, which rose 1.70%.

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2024 financial results after the ...